YPYeon-Jung Park

Yeon-Jung Park

*This is an algorithmically generated author record based on publicly available information.

Yeon-Jung Park has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Bark-Lynn Lew

    Department of Dermatology, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea

    1 shared publication
  • Chang Won Won

    Elderly Frailty Sarcopenia Research Center, Department of Family Medicine, College of Medicine, Kyung Hee University Medical Center, Kyung Hee University, Seoul, Republic of Korea

    1 shared publication
  • Hyung Eun Shin

    Department of Health Sciences and Technology, College of Medicine, Kyung Hee University , Seoul

    1 shared publication
  • Man S. Kim

    Translational-Transdisciplinary Research Center, Clinical Research Institute, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University

    1 shared publication
  • Soon-Hyo Kwon

    Center for Space Biomedical Science, NEXUS Institute, Kyung Hee University, Republic of Korea

    1 shared publication
  • Yoonsung Lee

    Department of Biomedical Science and Technology, Kyung Hee University, Republic of Korea

    1 shared publication

Latest Publications

  • Open Access

    Impact of Hydrochlorothiazide on Nonmelanoma Skin Cancer: A Distributed Network Analysis of 11 Real-world Databases

    by Yeon-Jung Park, Man S Kim, Yoonsung Lee, Bark-Lynn Lew, Soon-Hyo Kwon

    Park YJ, et al. Ann Dermatol. 2025 Aug;37:e32. https://doi.org/10.5021/ad.25.024


  • From a Solitary Blood-Derived Biomarker to Combined Biomarkers of Sarcopenia: Experiences From the Korean Frailty and Aging Cohort Study

    by Chang Won Won, Miji Kim, Hyung Eun Shin

    Sarcopenia is recognized as a complex and multifactorial disorder that includes nutritional deficiency, inactivity, proinflammatory status, hormonal changes, neurological degeneration, and metabolic disturbances. It’s pathogenesis is not fully understood. Therefore, identifying specific biomarkers of sarcopenia will help us understand its pathophysiology. The most frequently reported blood-derived biomarkers of sarcopenia are growth factors, neuromuscular junctions, endocrine systems, mitochondrial dysfunction, inflammation-mediated and redox processes, muscle protein turnover, blood metabolomics, and behavior-mediated biomarkers. Here, we address the implications of sarcopenia biomarkers based on our research experience with Korean Frailty and Aging Cohort Study cohort data. It includes free testosterone, myostatin, fibroblast growth factor 21 (FGF-21), growth differentiation factor 15 (GDF-15), procollagen type III N-terminal peptide (P3NP), creatinine-based biomarkers, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), brain-derived neurotrophic factor (BDNF), metabolites (proline, alanine, tryptophan), and multi-biomarker risk score. We attempted to explain the paradoxical findings of myostatin and FGF-21 levels in relation to sarcopenia. GDF-15 levels were associated with sarcopenia prevalence but not its incidence. Plasma P3NP and BDNF levels may be biomarkers of muscle quality rather than quantity. Lower erythrocyte eicosapentaenoic acid (EPA) and docosahexaenoic acid levels were associated with slow gait speed, and erythrocyte EPA levels were associated with low handgrip strength. We developed a multi-biomarker risk score for sarcopenia and found that its accuracy in diagnosing sarcopenia was higher than that of any single biomarker.